Jupiter Neurosciences (JUNS) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PRF Technologies is the larger company by market cap ($1.7 million vs $1.6 million), about 1.0 times the size. PRF Technologies converts more of its revenue into profit, with a net margin of -29541.2% versus -39662.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JUNS | PRFX |
|---|---|---|
| Share price | $1.24 | $0.4758 |
| Market cap | $1.63M | $1.66M |
| 1-day change | -18.75% | -23.68% |
| Forward P/E | 20.58 | — |
| EPS (TTM) | $-22.53 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.80K | $17.00K |
| Net income (latest FY) | $-8.64M | $-5.02M |
| Gross margin | 80.59% | -311.76% |
| Operating margin | -40873.19% | -30129.41% |
| Net margin | -39662.77% | -29541.18% |
| 52-week high | $97.73 | $7.95 |
| 52-week low | $1.20 | $0.46 |
| Distance from 52-week high | -98.74% | -94.02% |
| Average volume | 69.86K | 228.55K |
| Shares outstanding | 1.32M | 3.50M |
| Employees | 5 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRF Technologies is more profitable, keeping -29541.2 cents of every revenue dollar as net income versus -39662.8 cents for Jupiter Neurosciences.
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
JUNS vs PRFX FAQ
Which is bigger, Jupiter Neurosciences or PRF Technologies?
PRF Technologies (PRFX) is larger, with a market capitalization of $1.66M compared with $1.63M for Jupiter Neurosciences (JUNS).
Are Jupiter Neurosciences and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.